Rhode Island Faces Decision on Medicaid Coverage for GLP-1 Weight Loss Drugs
Rhode Island is considering whether to maintain Medicaid coverage for GLP-1 medications used to treat obesity, amid national debate over cost and access. The state has historically prioritized public health initiatives addressing health disparities and nutrition. The decision affects coverage policy for medications like Wegovy and Zepbound for Medicaid beneficiaries with obesity. Rhode Island's choice will impact managed care organizations' pharmacy benefits and utilization management protocols for this high-cost drug class.
GLP-1 obesity coverage decisions directly affect MCO pharmacy budgets, prior authorization protocols, and financial risk under capitated arrangements, with significant implications for care management strategies and medical loss ratios.
Pharmacy · Managed Care
You might also like